Loading clinical trials...
Loading clinical trials...
To determine if a drug regimen containing rifabutin will eradicate or decrease the numbers of Mycobacterium avium complex (MAC) organisms in blood, improve the symptoms associated with MAC infection, and increase survival in patients with AIDS. To assess the safety of the drug regimen.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Maricopa County Med Ctr
Phoenix, Arizona, United States
Bay Harbor Hosp
Harbor City, California, United States
Ctr for Special Immunology
Irvine, California, United States
Southwest Community Based AIDS Treatment Group - COMBAT
Los Angeles, California, United States
AIDS Community Research Consortium
Redwood City, California, United States
HIV Research Group
San Diego, California, United States
Davies Med Ctr
San Francisco, California, United States
San Francisco Veterans Administration Med Ctr
San Francisco, California, United States
Veterans Administration Med Ctr
Washington D.C., District of Columbia, United States
TheraFirst Med Ctrs Inc
Fort Lauderdale, Florida, United States
Last Updated
June 24, 2005
200
Estimated participants
Rifabutin
DRUG
Lead Sponsor
Pharmacia
NCT06694805
NCT04142047
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07428330